Nigella sativa: A potential antiosteoporotic agent

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Nigella sativa seeds (NS) has been used traditionally for various illnesses. The most abundant and active component of NS is thymoquinone (TQ). Animal studies have shown that NS and TQ may be used for the treatment of diabetes-induced osteoporosis and for the promotion of fracture healing. The mechanism involved is unclear, but it was postulated that the antioxidative, and anti-inflammatory activities may play some roles in the treatment of osteoporosis as this bone disease has been linked to oxidative stress and inflammation. This paper highlights studies on the antiosteoporotic effects of NS and TQ, the mechanisms behind these effects and their safety profiles. NS and TQ were shown to inhibit inflammatory cytokines such as interleukin-1 and 6 and the transcription factor, nuclear factor κB. NS and TQ were found to be safe at the current dosage for supplementation in human with precautions in children and pregnant women. Both NS and TQ have shown potential as antiosteoporotic agent but more animal and clinical studies are required to further assess their antiosteoporotic efficacies.

Original languageEnglish
Article number696230
JournalEvidence-based Complementary and Alternative Medicine
Volume2012
DOIs
Publication statusPublished - 2012

Fingerprint

Nigella sativa
Seeds
Osteoporosis
Fracture Healing
Bone Diseases
Interleukin-1
thymoquinone
Pregnant Women
Interleukin-6
Oxidative Stress
Anti-Inflammatory Agents
Transcription Factors
Cytokines
Inflammation
Safety
Therapeutics

ASJC Scopus subject areas

  • Complementary and alternative medicine

Cite this

@article{1d13add11cde4707b107248a010a817f,
title = "Nigella sativa: A potential antiosteoporotic agent",
abstract = "Nigella sativa seeds (NS) has been used traditionally for various illnesses. The most abundant and active component of NS is thymoquinone (TQ). Animal studies have shown that NS and TQ may be used for the treatment of diabetes-induced osteoporosis and for the promotion of fracture healing. The mechanism involved is unclear, but it was postulated that the antioxidative, and anti-inflammatory activities may play some roles in the treatment of osteoporosis as this bone disease has been linked to oxidative stress and inflammation. This paper highlights studies on the antiosteoporotic effects of NS and TQ, the mechanisms behind these effects and their safety profiles. NS and TQ were shown to inhibit inflammatory cytokines such as interleukin-1 and 6 and the transcription factor, nuclear factor κB. NS and TQ were found to be safe at the current dosage for supplementation in human with precautions in children and pregnant women. Both NS and TQ have shown potential as antiosteoporotic agent but more animal and clinical studies are required to further assess their antiosteoporotic efficacies.",
author = "Shuid, {Ahmad Nazrun} and Norazlina Mohamed and {Naina Mohamed}, Isa and Faizah Othman and Farihah Suhaimi and {Mohd Ramli}, {Elvy Suhana} and Norliza Muhammad and Soelaiman, {Ima Nirwana}",
year = "2012",
doi = "10.1155/2012/696230",
language = "English",
volume = "2012",
journal = "Evidence-based Complementary and Alternative Medicine",
issn = "1741-427X",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Nigella sativa

T2 - A potential antiosteoporotic agent

AU - Shuid, Ahmad Nazrun

AU - Mohamed, Norazlina

AU - Naina Mohamed, Isa

AU - Othman, Faizah

AU - Suhaimi, Farihah

AU - Mohd Ramli, Elvy Suhana

AU - Muhammad, Norliza

AU - Soelaiman, Ima Nirwana

PY - 2012

Y1 - 2012

N2 - Nigella sativa seeds (NS) has been used traditionally for various illnesses. The most abundant and active component of NS is thymoquinone (TQ). Animal studies have shown that NS and TQ may be used for the treatment of diabetes-induced osteoporosis and for the promotion of fracture healing. The mechanism involved is unclear, but it was postulated that the antioxidative, and anti-inflammatory activities may play some roles in the treatment of osteoporosis as this bone disease has been linked to oxidative stress and inflammation. This paper highlights studies on the antiosteoporotic effects of NS and TQ, the mechanisms behind these effects and their safety profiles. NS and TQ were shown to inhibit inflammatory cytokines such as interleukin-1 and 6 and the transcription factor, nuclear factor κB. NS and TQ were found to be safe at the current dosage for supplementation in human with precautions in children and pregnant women. Both NS and TQ have shown potential as antiosteoporotic agent but more animal and clinical studies are required to further assess their antiosteoporotic efficacies.

AB - Nigella sativa seeds (NS) has been used traditionally for various illnesses. The most abundant and active component of NS is thymoquinone (TQ). Animal studies have shown that NS and TQ may be used for the treatment of diabetes-induced osteoporosis and for the promotion of fracture healing. The mechanism involved is unclear, but it was postulated that the antioxidative, and anti-inflammatory activities may play some roles in the treatment of osteoporosis as this bone disease has been linked to oxidative stress and inflammation. This paper highlights studies on the antiosteoporotic effects of NS and TQ, the mechanisms behind these effects and their safety profiles. NS and TQ were shown to inhibit inflammatory cytokines such as interleukin-1 and 6 and the transcription factor, nuclear factor κB. NS and TQ were found to be safe at the current dosage for supplementation in human with precautions in children and pregnant women. Both NS and TQ have shown potential as antiosteoporotic agent but more animal and clinical studies are required to further assess their antiosteoporotic efficacies.

UR - http://www.scopus.com/inward/record.url?scp=84867002901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867002901&partnerID=8YFLogxK

U2 - 10.1155/2012/696230

DO - 10.1155/2012/696230

M3 - Article

C2 - 22973403

AN - SCOPUS:84867002901

VL - 2012

JO - Evidence-based Complementary and Alternative Medicine

JF - Evidence-based Complementary and Alternative Medicine

SN - 1741-427X

M1 - 696230

ER -